Anteris Technologiescontinues to meet its operations schedule despite the impact of COVID-19 global restrictions. Countermeasures the Company adopted early in the pandemic have ensured the safety and well-being of staff without significantly compromising operations. The greatest impact remains on travel restrictions to medical conferences and face-to-face meetings with potential partners important to promoting the Company's TAVR development programme. Notwithstanding these impediments, Anteris is committed to concluding partnership deals for TAVR development this year as outlined in its fiscal year 2019 Annual Report. Also, in 2020, Anteris aims to conclude partnership deals for supply of ADAPT® tissue. Product innovation continues, led by the TAVR programme. Other large market opportunities are at varying stages of design development, regulatory clearance and user evaluation. In manufacturing, the Company is continually improving efficiency to reduce costs and maximize margins and yields. Specifically, regarding its 2020 objectives, Anteris commenced: in March, its 15 patient clinical study of its DurAVRTM valve in surgical aorta valve replacement (SAVR). The Federal Agency for Medicines and Health Products (FAMHP) of Belgium granted approval to conduct the first-in-human study on 11 March 2020; in May, its preclinical study comparing anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves. Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes; and in June, the feasibility study in three pigs of its proprietary DurAVRTM Transcatheter Heart Valve as part of a transcatheter aortic valve replacement (TAVR) study in a porcine model to be completed by year end. The Company, also, completed: in February, the transfer of its unique Sterilisation Method (as part of its ADAPT® tissue treatment process) to 4C Medical Technologies Inc. for an additional USD 1 million (USD 0.44 million previously received) to use the technology to sterilise the ADAPT® tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValveTM system device; and in March, the consolidation of its issued capital as part of the Company's restructuring and recapitalisation plan.